{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:51:43Z","timestamp":1783047103184,"version":"3.54.6"},"reference-count":41,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the risk of acute kidney injury (AKI) in subjects initiating statin therapy for primary prevention of cardiovascular disease (CVD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A nationwide cohort study using French hospital discharge and claims databases was performed, studying subjects from the general population aged 40 to 75 years in 2009, with no history of CVD and no lipid\u2010lowering drugs during the preceding 3\u2010year period, followed for up to 7 years. Exposure to statins (type, dose, and time since first use) and to other drugs for CVD risk was assessed. The primary outcome was hospital admission for AKI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort included 8 236 279 subjects, 818 432 of whom initiated a statin for primary prevention. During 598 487 785 person\u2010months exposed to statins, 700 events were observed, corresponding to an incidence of AKI of 4.59 per 10 000 person\u2010years (7.01 in men, 3.01 in women). AKI mainly occurred in the context of organ failure, sepsis, and genitourinary disease. A 19% increased rate of AKI (hazard ratio = 1.19, 95%CI: 1.08\u20101.31) was observed in men exposed to statins, whereas no increase in the overall risk of AKI was observed in women. However, exposure to high\u2010potency statins was associated with a 72% to 116% increased risk in both genders and a dose\u2010effect relationship observed for rosuvastatin and atorvastatin. No temporal pattern of occurrence nor interaction with drugs for CVD risk was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although the overall risk of AKI appears moderately increased, more attention should be paid to renal function in subjects taking statins for primary prevention both in clinical practice and from a research viewpoint.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4898","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T10:05:09Z","timestamp":1568369109000},"page":"1583-1590","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7674-7192","authenticated-orcid":false,"given":"Jo\u00ebl","family":"Coste","sequence":"first","affiliation":[{"name":"Department of Public Health Studies French National Health Insurance Fund (CNAM)  Paris France"},{"name":"Department of Epidemiology of Health Products French National Agency for Medicines and Health Products Safety (ANSM)  Saint\u2010Denis France"},{"name":"Biostatistics and Epidemiology Unit Assistance Publique\u2010H\u00f4pitaux de Paris H\u00f4pitaux Universitaires Paris Centre  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[{"name":"Nephrology Department Assistance Publique\u2010H\u00f4pitaux de Paris H\u00f4pital Europ\u00e9en Georges Pompidou  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Rudnichi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Health Products French National Agency for Medicines and Health Products Safety (ANSM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray\u2010Spira","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Health Products French National Agency for Medicines and Health Products Safety (ANSM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Pouchot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Assistance Publique\u2010H\u00f4pitaux de Paris H\u00f4pital Europ\u00e9en Georges Pompidou  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Giral","sequence":"additional","affiliation":[{"name":"Department of Endocrinology\u2010Metabolism, Assistance Publique\u2010H\u00f4pitaux de Paris H\u00f4pital de la Piti\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Health Products French National Agency for Medicines and Health Products Safety (ANSM)  Saint\u2010Denis France"},{"name":"Versailles Saint\u2010Quentin\u2010en\u2010Yvelines University  Versailles France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.15450"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60716-8"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1681"},{"key":"e_1_2_5_6_1","article-title":"Statins for primary prevention and rhabdomyolysis: a nationwide cohort study in France","volume":"1","author":"Coste J","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16513-6"},{"key":"e_1_2_5_8_1","volume-title":"Crestor (rosuvastatin calcium)","author":"Food and Drug Administration"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2197"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f880"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.11.031"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1423"},{"key":"e_1_2_5_15_1","volume-title":"Survival analysis using SAS: a practical guide (second edition)","author":"Allison PD","year":"2010"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.03.046"},{"key":"e_1_2_5_17_1","article-title":"CRESTOR (Rosuvastatin calcium) NDA 21\u2010366 JUPITER","author":"Roberts MD","year":"2009","journal-title":"United States Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-12-201306180-00004"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.140950"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.071"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.555482"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248407306676"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.08.037"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353175"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy182"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70246-3"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000363202"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3743"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.05.010"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0548"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281348"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"e_1_2_5_34_1","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"5","author":"Palmer SC","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11454"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10981016"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201711070"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.10.022"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001398"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003674"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1504547"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4898","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4898","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:44:13Z","timestamp":1694184253000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/pds.4898"],"URL":"https:\/\/doi.org\/10.1002\/pds.4898","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"2019-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}